MICHAEL DEHNER: Open Payments
NPI 1275903239 · COLUMBUS, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$407 in 21 payments from 11 companies in 2025. Trend: 2023 $520 · 2024 $542 · 2025 $407
Food & beverage: $407
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 4 | $86 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $68 |
| Vanda Pharmaceuticals Inc. | 2 | $40 |
| Neurocrine BioSciences, Inc. | 2 | $36 |
| Teva Pharmaceuticals USA, Inc. | 2 | $36 |
| ABBVIE INC. | 2 | $32 |
| Alkermes, Inc. | 2 | $30 |
| Supernus Pharmaceuticals, Inc. | 1 | $22 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Lundbeck LLC | 1 | $20 |
Products named: CAPLYTA, INVEGA SUSTENNA, REXULTI, FANAPT, INGREZZA, AUSTEDO XR, SPRAVATO, VRAYLAR.
Industry payments across GA — which companies pay providers there.
